MedTrace Logo

Super Hypofractionated Irradiation for Whole Breast Treatment

NCT04926766 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2024-12-20

No results posted yet for this study

Summary

The purpose of this trial is to investigate the safety and efficacy of super hypofractionated whole breast irradiation (SHF-WBI) in breast cancer patients treated with breast conserving surgery. Eligible breast cancer patients will be followed for at least 5 years to evaluate the acute and late radiation-induced toxicities, locoregional recurrence, distant metastasis, death, contralateral breast cancer and quality of life.

Conditions

Interventions

RADIATION

External Beam radiotherapy using IMRT technique

2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Jiayi Chen, PhD, MD · Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medcine

  • Lu Cao, PhD, MD · Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medcine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-23
Primary Completion
2024-01-10
Completion
2028-07-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04926766 on ClinicalTrials.gov